Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$129.50M$129.50Mderived+81.5% vs Q4 2024 Net Income$17.40M$17.40MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$18,387,000N/M Operating Cash Flowderived$26,185,000N/M Free Cash Flowderived$26,185,000N/M Margins · derivedOperating margin14.2%+24.9 pt vs Q4 2024
Net margin13.4%+28.5 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 25, 2026 · 56 d after period end